{"nctId":"NCT02344628","briefTitle":"Comparison of Two Different Doses of Azithromycin for Treatment of Yaws","startDateStruct":{"date":"2015-06"},"conditions":["Yaws"],"count":583,"armGroups":[{"label":"AZT30","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Azithromycin"]},{"label":"AZT20","type":"EXPERIMENTAL","interventionNames":["Drug: Azithromycin"]}],"interventions":[{"name":"Azithromycin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 6 to 16 years\n* Clinical lesion consistent with primary or secondary yaws -Primary ulcer or papilloma\n* Dually-Positive Chembio DPP Syphilis Screen \\& Confirm\n* Informed Consent and Assent (for children 12-16 years)\n\nExclusion Criteria:\n\n1. Known allergy to azithromycin or macrolides.\n2. Treatment with long-acting penicillin or alternative antibiotic with activity against T. pallidum within the last 3 months (ceftriaxone, azithromycin or doxycycline, amoxicillin).\n3. Patients with current treatment with any drugs likely to interact with the study medication.\n4. Patients who are unable to take oral medication or having gastrointestinal disease likely to interfere with drug absorption.\n5. Patients who may not be able to comply with the requirements of the study protocol including follow up visits.\n6. Patients who are not willing to give informed consent (patient and/or parent/legal representative), or who withdraw consent.","healthyVolunteers":false,"sex":"MALE","minimumAge":"6 Years","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Clinical and Serological Cure","description":"Clinical resolution of skin lesion at 4 weeks and at least four-fold decline in Rapid Plasma Reagin titre or seroreversion at 6-month (compared to baseline) in T.pallidum subsp. pertenue Polymerase Chain Reaction-confirmed subjects with yaws.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinical and Serological Cure in Latent Yaws","description":"Clinical resolution of skin lesion at 4 weeks and at least four-fold decline in Rapid Plasma Reagin titre or seroreversion at 6-month (compared to baseline) in T.pallidum subsp. pertenue Polymerase Chain Reaction-negative.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"To compare the incidences and relative risk of all Adverse Events (AEs), including treatment-related AEs, Serious Adverse Events (SAEs) and grade 3-4 toxicity in patients treated with AZT20 and AZT30 regimens","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":291},"commonTop":["Abdominal Discomfort","Dizziness","Diarrhoea","Nausea","Headache"]}}}